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Abstract: Most of the late diabetic complications such as retinopathy, nephropathy, and neuropathy, 
have their basis in disturbed microvascular function. Structural and functional changes in the micro-
circulation are present in diabetes mellitus irrespective of the organ studied, and the pathogenesis 
is complex. Endothelial dysfunction, characterized by an imbalance between endothelium-derived 
vasodilator and vasoconstrictor substances, plays an important role in the pathogenesis of diabetic 
microangiopathy. Increased circulating levels of endothelin-1 (ET-1), a potent vasoconstrictor 
peptide, has been found in patients with diabetes, and a positive correlation between plasma ET-1 
levels and microangiopathy in patients with type 2 diabetes has been demonstrated. In addition to 
its direct vasoconstrictor effects, enhanced levels of ET-1 may contribute to endothelial dysfunction 
through inhibitory effects on nitric oxide (NO) production. Vascular endothelial dysfunction may 
precede insulin resistance, although the feature of insulin resistance syndrome includes factors that 
have negative effects on endothelial function. Furthermore, ET-1 induces a reduction in insulin 
sensitivity and may take part in the development of the metabolic syndrome. In the following, the 
mechanisms by which ET-1 contributes to the development of diabetic microangiopathy and the 
potentially beneﬁ  cial effect of selective ETA receptor antagonists are discussed.
Keywords: endothelin-1, diabetes mellitus, microcirculation, diabetic microangiopathy, 
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Introduction
Incidence and prevalence rates of type 2 diabetes are rising in most countries (King 
et al 1998). Diabetes mellitus is associated with an increased risk of cardiovascular 
diseases related to both macro- and microangiopathy, eg, myocardial infarction, 
peripheral arterial occlusive disease, stroke, retino-, neuro-, and nephropathies, 
causing considerable disability and premature death in individuals with diabetes. 
Diabetic skin microangiopathy contributes to the development of chronic foot ulcers, 
a common and severe complication often leading to major disability and increased 
mortality and also frequently resulting in amputation of the leg (Jeffcoate et al 2003). 
Endothelium-dependent vasodilation is impaired in the skin microcirculation of patients 
with type 2 diabetes (Caballero et al 1999). Furthermore, autonomic neuropathy may 
cause increased shunting of blood through arteriovenous anastomoses and lead to 
impaired circulation through nutritive capillaries (Boulton et al 1982; Fagrell et al 
1999; Tooke 2000). Endothelial dysfunction, characterized by an imbalance between 
endothelium-derived vasodilator and vasoconstrictor substances, plays an important 
role in the pathogenesis of vascular complications in diabetes, including microangi-
opathy (Tooke 1995; Creager et al 2003; Luscher et al 2003).
Diabetic microangiopathy
The microcirculation comprises the arterioles, capillaries, venules, and lymphatics, 
all 100 μm in diameter. These vessels are crucial for maintaining tissue metabolism. Vascular Health and Risk Management 2008:4(5) 1062
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Structural and functional changes in the microcirculation 
are present in diabetes mellitus irrespective of the organ 
studied. We have shown that functional disturbances in 
the skin microcirculation of the ﬁ  ngers are present three 
years after the onset of type 1 diabetes, and the majority of 
the patients have developed disturbances after 7–12 years 
(Kalani et al pers comm). The pathophysiology of diabetic 
microangiopathy is complex in that it involves not only 
metabolic, but also genetic factors. Subjects with diabetes 
heredity show impaired microvascular responses to both 
endothelium- and nonendothelium-dependent stimuli in the 
skin microcirculation in spite of normal body dimensions, 
normal glucose tolerance, and normal insulin sensitivity 
(Jörneskog et al 2005). Early on in the course of the dis-
ease, microvascular perfusion is increased in many organs 
under resting conditions (Tooke 1983, 1986). A cutaneous 
microvascular overperfusion occurs in the limbs, but most 
of the blood ﬂ  ow under normal thermal conditions passes 
through arteriovenous shunts, bypassing the nutritive cap-
illary bed and leading to so-called “capillary ischemia” 
(Boulton et al 1982; Tooke 1983; Fagrell et al 1999). 
Increased skin microvascular perfusion has been shown to 
be related to poor glycemic control (Gundersen et al 1974; 
Tymms et al 1988; Jörneskog et al 1998). It should be 
pointed out that the early microvascular hyperemia occurs 
only under resting conditions, while under conditions that 
stress the microcirculation, eg, tissue injury or a period of 
arterial occlusion, a limited hyperemic response is observed 
(Rayman et al 1986; Walmsley et al 1989; Sandeman et al 
1991). This has been clearly demonstrated by investiga-
tions of the nutritive skin capillary ﬂ  ow (capillary blood 
cell velocity; CBV) in diabetic feet using videophotometric 
capillaroscopy, along with measurements of the total skin 
microcirculation by laser Doppler ﬂ  uxmetry (LDF), dem-
onstrating reduced skin capillary hyperemia in terms of 
the post-occlusive peak value obtained and the time taken 
to reach peak ﬂ  ow (Walmsley et al 1989; Tur et al 1991; 
Jörneskog 1995).
There are, however, probably differences in the pathogen-
esis of microangiopathy between type 1 and type 2 diabetes. 
In type 2 diabetes, there is a complex interaction between 
impaired insulin sensitivity, vascular endothelial dysfunc-
tion, and hypertension, which seems to play an important 
role in the development of functional disturbances in the 
microcirculation. Impaired insulin sensitivity is associated 
with a modiﬁ  cation of arterial resistance and increased 
peripheral microvascular resistance, which contributes to 
the excessive prevalence of hypertension in type 2 diabetes. 
In these patients, an increased peripheral microvascular 
resistance occurs with even minor degrees of impaired 
glucose tolerance, which coexists with disturbed capillary 
pressure autoregulation, leading to the development of irre-
versible structural changes in the microvasculature (Gall et al 
1991; Jaap et al 1994; Shore et al 1994).
Endothelin-1
Endothelin-1 (ET-1) is the principal cardiovascular isoform 
of the endothelin system (Yanagisawa et al 1988). Vascular 
ET-1 is produced primarily in the endothelium, although 
it can also be produced in vascular smooth muscle cells 
(VSMC), macrophages, leukocytes, cardiomyocytes, and 
ﬁ  broblasts (Resink et al 1990; Properzi et al 1995). In the 
kidney, tubular epithelial cells, mesangial cell, and podocytes 
are capable of ET-1 release (Kohan 1997). Several mecha-
nisms are involved in the clearance of ET-1 from plasma, 
including endocytosis in the lungs, enzymatic degradation, 
degradation of the endothelin B-receptor-ligand complex, and 
enzymatic processes in the kidney and liver (Anggard et al 
1989; Abassi et al 1992; Johnström et al 2005). Two recep-
tor subtypes, endothelin A- and B-receptors (ETA and ETB), 
mediate the effects of ET-1. Vascular smooth muscle cells 
express both ETA and ETB, while endothelial cells express 
primarily ETB (Molenaar et al 1993). On smooth muscle 
cells, ETA mediates vasoconstriction and mitogenesis, while 
ETB receptor has a dual function and has been shown to 
cause both vasoconstriction and vasodilation (Sakurai et al 
1992; Seo et al 1994). ETA receptor activation contributes 
to coronary constrictor tone and peripheral and coronary 
endothelial dysfunction (Kyriakides et al 2000; Halcox et al 
2001). In isolated human internal mammary and porcine 
coronary arteries, ETB receptor mediates ET-1-induced 
vasoconstriction (Seo et al 1994). In healthy humans, selec-
tive ETB receptor antagonism increases peripheral vascular 
resistance, which means that vasodilation is the favored 
ETB pathway (Strachan et al 1999). However, the balance 
between vasodilator and vasoconstrictor ETB pathways may 
be altered in pathological conditions (Cardillo et al 1999; 
Pernow et al 2000).
ET-1 is one of the most potent vasoconstrictors 
described and has been suggested to be involved in the 
development of cardiovascular disease. ET-1 also has pro-
inﬂ  ammatory and proﬁ  brotic effects, which may contribute 
to the pathogenesis of cardiovascular disease. Endogenous 
ET-1 is important for maintaining vascular tone, and 
enhanced endogenous ET-1 has been demonstrated in 
hypertension, coronary artery disease, and heart failure Vascular Health and Risk Management 2008:4(5) 1063
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(Cardillo et al 1999, 2000; Cowburn et al 1999; Love et al 
2000; Nohria et al 2003).
The role of endothelin-1 in diabetic 
microangiopathy
The pathophysiology of diabetic microangiopathy is complex 
and many important aspects of it still are not fully under-
stood. The major microvascular complications of diabetes are 
nephropathy, retinopathy, neuropathy, and skin microangi-
opathy. Both metabolic and hemodynamic factors contribute 
to the development of diabetic microvascular complications 
(Cooper 1998; Groop et al 2005), which, in spite of similar 
ﬁ  nal clinical manifestations in both type of diabetes, prob-
ably have different pathophysiological pathways regarding 
the organ and/or complication studied. In type 2 diabetes, 
endothelial dysfunction is an early feature of the disease, 
linking cardiovascular risk factors and insulin resistance 
in different pathways to clinically manifest cardiovascular 
complications (Jansson 2007; Rask-Madsen et al 2007). The 
vascular endothelium maintains vascular tone and has impor-
tant hemostatic function, and endothelial dysfunction is of 
major importance in the pathogenesis of atherosclerosis and 
diabetic angiopathy (Tooke et al 2000; Rask-Madsen et al 
2007). Several studies support the hypothesis that endothelial 
dysfunction is a precursor of type 2 diabetes, indicating that 
vascular endothelial dysfunction may precede insulin resis-
tance, although the features of insulin resistance syndrome 
include factors that have negative effects on endothelial 
function (Tooke et al 2000; Groop et al 2005; Jansson 2007; 
Rask-Madsen et al 2007). Impaired endothelial-dependent 
and independent microvascular reactivity has also been 
demonstrated in healthy subjects with risk factors for type 
2 diabetes (Caballero et al 1999; Jörneskog et al 2005). One 
important feature of endothelial dysfunction is an increased 
production and biological activity of the potent vasoconstric-
tor and proinﬂ  ammatory peptide ET-1. Elevated levels of 
ET-1 are found in patients with type 2 diabetes (Takahashi 
et al 1990; Verhaar et al 1998; Mather et al 2002), and 
ET-1-induced reduction in insulin sensitivity may take part 
in the development of the metabolic syndrome (Ahlborg et al 
2002). In diabetes mellitus, a primary disturbance in ET-1 
production from vascular endothelium exists as an early 
phenomenon rather than a result of advanced stage of the 
disease (Donatelli et al 1994; Anfossi et al 2007).
Furthermore, ET-1 may contribute to the development of 
endothelial dysfunction, and consequently insulin resistance, 
by increasing the production of reactive oxygen species, 
mainly superoxide anion, in the vasculature. This is mainly 
dependent upon the activation of NADPH oxidase protein 
expression and activity (Wedgwood et al 2001; Li et al 2003; 
Romero et al 2008).
Diabetic nephropathy
ET-1 is secreted by glomerular endothelial cells, mesangial 
cells, and epithelial cells. Activation of endothelin receptors 
in the kidney leads to constriction of renal vessels, inhibition 
of salt and water reabsorption, and enhanced glomerular pro-
liferation. Alterations in ET-1, at both mRNA and receptor 
levels are seen in animal models of diabetes. Several human 
studies show a correlation between plasma or urinary levels 
of ET-1 and signs of diabetic nephropathy at different stages 
in terms of an increased glomerular ﬁ  ltration rate, mesangial 
expansion, macro- and/or microalbuminuria, and uremia (Lee 
et al 1994; De Mattia et al 1998; Ak et al 2001; Candido 
et al 2002; Zanatta et al 2008). However, most of the inter-
ventional studies on selective or dual endothelin receptor 
blockers have been done in animal models with encouraging 
results (Chade et al 2006; Sasser et al 2007).
Diabetic neuropathy
Diabetic neuropathy is one of the most frequent and expensive 
complications of diabetes. The peripheral sensorimotor and 
autonomic neuropathies play an important role in the patho-
genesis of diabetic foot ulceration. Sympathetic neuropathy 
also results in arteriovenous shunting, leading to impaired 
blood ﬂ  ow through nutritive capillaries. Both hemodynamic 
and metabolic factors contribute to the development of 
diabetic neuropathy. Microvascular dysfunction is seen at 
an early stage in the peripheral nerve, which contributes to 
impaired endoneurial blood ﬂ  ow, leading to destruction of 
neuronal and Schwann cells and, ﬁ  nally, nerve degeneration 
(Low et al 1989; Cameron et al 1991, 1995). In patients with 
diabetes, endoneurial microangiopathy, and in particular base-
ment membrane thickening, is related to clinical and neuro-
physiological measures of neuropathy. Endoneurial capillary 
microangiopathy presages deterioration in glucose tolerance 
and seems to be an early and persistent feature in the processes 
underlying diabetic peripheral neuropathy (Thrainsdottir 
et al 2003). Interestingly, diabetic patients without evidence 
of neuropathy demonstrate endoneurial microangiopathy. 
Microangiopathy may therefore precede the development of 
peripheral neuropathy (Giannini et al 1995).
ET-1 contributes to endothelial abnormalities and the 
altered balance of vasodilation and vasoconstriction in favor 
of the latter in diabetes. Furthermore, endothelin receptors are 
expressed in neurons and glial cells and are probably involved Vascular Health and Risk Management 2008:4(5) 1064
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in the transduction of nociceptive information (Gokin et al 
2001). ETA receptor blockade attenuates tactile allodynia in 
the streptozotocin-induced diabetic rat, suggesting that ETA 
receptors may contribute to the development of peripheral 
neuropathy in experimental diabetes (Jarvis et al 2000). 
Interestingly, a protective role for ETB receptors following 
neuronal injury has been described (Siren et al 2002; Berti-
Mattera et al 2006).
Diabetic retinopathy
Diabetic retinopathy is a potentially sight-threatening 
complication that develops in nearly all patients with dia-
betes. Ocular tissues, eg, vascular and extravascular sites in 
the retina are a rich source of ET-1 expression, and ET-1 
contributes to abnormal retinal hemodynamics in diabetic 
retinopathy (Kohner et al 1995; Pang et al 1997). Results 
from several studies in streptozotocin-induced diabetic rats 
have suggested a role of ET-1 in the pathogenesis of diabetic 
retinopathy (Chakrabarti et al 1997, 1998). An interac-
tion between ET-1 and vascular endothelial growth factor 
(VEGF) has also been reported, and some positive results 
of treatment with endothelin receptor blockers have raised 
interest in these substances as potentially therapeutic agents 
(Masuzawa et al 2006). However, most of the studies on the 
role of ET-1 in the pathogenesis of diabetic retinopathy and 
the importance of endothelin blockers in the treatment of this 
serious complication have been done in animal models. There 
is, however, sufﬁ  cient evidence that strongly links ET-1 to 
the pathogenesis of diabetic retinopathy.
Diabetic skin microangiopathy
The pathogenesis of diabetic skin microangiopathy is complex 
(Figure 1). Functional diabetic microangiopathy is character-
ized by reduced microvascular reactivity and increased blood 
ﬂ  ow through arteriovenous shunts leading to an impaired nutri-
tive capillary circulation, so-called capillary ischemia (Boulton 
et al 1982; Fagrell et al 1999; Tooke 2000). Impaired nutritive 
capillary circulation is especially pronounced in patients with 
peripheral arterial occlusive disease (Jörneskog et al 1995). 
A state of hypercoagulation and impaired ﬁ  brinolysis is also 
present in diabetic patients and may contribute to the deteriora-
tion of the skin microcirculation (Kalani et al 2007).
Recently, we have shown that ETA receptor blockade by 
BQ123 markedly increases the nutritive skin microcirculation 
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Figure 1 Pathogenesis of diabetic skin microangiopathy.Vascular Health and Risk Management 2008:4(5) 1065
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in patients with type 2 diabetes and microangiopathy 
(Settergren et al 2008). The results suggest that ET-1, through 
activation of the ETA receptor, is of importance for the regula-
tion of the microcirculation in diabetic patients with micro-
angiopathy. The skin nutritive microcirculation determined 
by nailfold capillary microscopy and the hyperemic response, 
ie, the peak value of the CBV following arterial occlusion, 
increased signiﬁ  cantly during ETA receptor blockade, indi-
cating improved microvascular reactivity (Figure 2a–b) 
(Settergren et al 2008). Interestingly, the increase in CBV 
during selective ETA receptor blockade was more pronounced 
in type 2 diabetic patients with a high body mass index (BMI) 
and low levels of insulin-like growth factor binding protein-1 
(IGFBP-1), supporting the existence of a close relationship 
between insulin resistance and increased ET-1 activity. It is 
noteworthy that administration of the selective ETA receptor 
antagonist did not affect CBV in the nondiabetic control group. 
This supports the notion that the ET-1 system is upregulated in 
patients with type 2 diabetes and that ETA receptor blockade 
exerts hemodynamic effects only under such conditions.
Enhanced ET-1–mediated vasoconstriction of precapillary 
resistance vessels leads to impaired blood ﬂ  ow through nutri-
tive capillaries and increased arteriovenous shunting in patients 
with type 2 diabetes. These patients are prone to arterial hyper-
tension, partly due to vasoconstriction of precapillary resistance 
vessels, leading to an increased capillary blood pressure (Fegan 
et al 2003) due to disturbed autoregulation of capillary pressure 
as a consequence of insulin resistance. A reduction in capillary 
blood pressure, as a consequence of reduced arteriovenous 
shunt ﬂ  ow and an increased arteriovenous pressure differ-
ence, might increase the capillary blood circulation (Fegan 
et al 2003). The effects of selective ETA receptor blockade on 
the skin microcirculation may be a consequence of blocking 
the precapillary constrictor effects of ET-1 mediated by ETA 
receptors. Furthermore, improvements in peak CBV reﬂ  ect 
vasodilation at the precapillary level, indicating improved 
precapillary and capillary endothelial function.
Diabetic foot ulcers in the presence of peripheral arte-
rial disease threatens both life and limb in these patients. 
However, the local nutritive skin microcirculation is severely 
deteriorated in diabetic patients with peripheral arterial occlu-
sive disease and new treatments are urgently needed. We 
conducted a pilot study to investigate whether ETA receptor 
blockade improves peripheral tissue perfusion in diabetic 
patients with critical limb ischemia. During infusions of the 
selective ETA receptor blocker BQ123, transcutaneous oxygen 
tension (TcPO2) at the dorsum of the foot and toe blood pres-
sure (TBP) increased signiﬁ  cantly (Figure 3a-b) (Kalani et al 
2008). The increased local skin oxygenation during infusions 
of BQ123 suggests an improved nutritive capillary circulation. 
TcPO2 may partly reﬂ  ect local nutritive capillary circulation 
and has been suggested for the evaluation of peripheral arte-
rial disease and the prediction of ulcer outcomes (Kalani et al 
1999). Increased TBP during ETA receptor blockade may be 
due to vasodilation of precapillary resistance vessels. The 
observed effect of ETA receptor blockade on peripheral tissue 
perfusion in these patients may be a consequence of block-
ing the precapillary constrictor effects of ET-1 mediated by 
ETA receptors. Furthermore, ETA receptor blockade has been 
shown to improve endothelium-dependent vasodilation by 
enhancing the bioavailability of nitric oxide, which appears 
to be of importance for microvascular function in diabetes 
(Mather et al 2002). In addition to the increased levels of ET-1 
in patients with diabetes, as compared to nondiabetic controls 
(Settergren et al 2008), there are also indications of upregula-
tion of ET receptors in diabetes (Khan et al 2003). The marked 
increase in peripheral blood ﬂ  ow observed following BQ123 
infusion in the diabetic patients may therefore be related to 
Figure 2 Effect of BQ123 on resting capillary blood cell velocity (CBV) (a) and peak capillary blood cell velocity following a 1-min arterial occlusion (b) in patients with 
type 2 diabetes (n = 10) and nondiabetic controls (n = 8). Data are shown as the mean and SEM. A signiﬁ  cant difference between groups in the change in resting CBV and peak 
CBV, respectively, following a 60-min infusion of BQ123 is shown. Copyright © 2008. Reproduced with the kind permission of Karger AG, Basel from Settergren M, Pernow J, 
Brismar K, et al 2008. Endothelin-A receptor blockade improves nutritive skin capillary circulation in patients with type 2 diabetes and albuminuria. J Vasc Res, 45:295–302.
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increased production of ET-1 as well as an upregulation of 
ETA receptors mediating vasoconstriction.
Conclusions
Disturbed microvascular function in diabetes, ie, diabetic 
microangiopathy, plays an important role in the pathogenesis 
of speciﬁ  c complications in different organs. Impaired nutri-
tive skin microcirculation has been demonstrated in both the 
diabetic hand and foot and might contribute to the develop-
ment of such complications as sensorimotor neuropathy and 
nonhealing ulcers. ET-1 is a potent vasoconstrictor, proin-
ﬂ  ammatory, and mitogenic peptide produced by endothelial 
cells, VSMC, and inﬂ  ammatory cells. The production and the 
plasma levels of ET-1 are elevated in patients with diabetes, 
and a positive correlation between plasma ET-1 levels and 
diabetic microangiopathy has been reported, suggesting a 
potential role of the endothelin system in the pathophysiol-
ogy of vascular complications in diabetes. A large body of 
evidence from animal models and human studies indicates 
that ET-1 is causally involved in the pathogenesis of dia-
betic microangiopathy, but the potential of ET-1 blockers 
in the treatment of diabetic microangiopathy has not been 
investigated in human studies. Nevertheless, recent results 
from our studies in patients with diabetes indicate that target-
ing the ET-1 system might be of importance in the treatment 
of complications related to diabetic microangiopathy.
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